Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma.
a Department of Oncology , Aarhus University Hospital , Aarhus , Denmark.
Maibritt P
MP
Holm
b Nuclear Medicine and PET centre, Aarhus University Hospital , Aarhus , Denmark.
Karin
K
Hjorthaug
c Department of Pathology , Aarhus University Hospital , Aarhus Denmark.
Steen
S
Bærentzen
a Department of Oncology , Aarhus University Hospital , Aarhus , Denmark.
Akmal A
AA
Safwat
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000079963:Brentuximab Vedotin; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000097:blood* / Q000276:immunology; D008875:Middle Aged; D017211:Treatment Failure
D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin